120450-98-8

Basic information

• Product Name: 2-Thiopheneethanimidoyl chloride, N-hydroxy-alpha-oxo- (9CI)
• Synonyms: 2-Thiopheneethanimidoyl chloride, N-hydroxy-alpha-oxo- (9CI)
• CAS NO: 120450-98-8
• Molecular Formula: C₆H₄ClNO₂S
• Molecular Weight: 189.61946
• Product Categories: ACETYLHALIDE
• Mol File: 120450-98-8.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Thiopheneethanimidoyl chloride, N-hydroxy-alpha-oxo- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Thiopheneethanimidoyl chloride, N-hydroxy-alpha-oxo- (9CI)(120450-98-8)
• EPA Substance Registry System: 2-Thiopheneethanimidoyl chloride, N-hydroxy-alpha-oxo- (9CI)(120450-98-8)

Safety Data

• Hazardous Substances Data: 120450-98-8(Hazardous Substances Data)

Upstream product

• 128694-37-1 2-oxo-2-(thiophen-2-yl)acetaldehyde oxime 
• 88-15-3 2-Acetylthiophene 

Downstream Products

• 1426835-20-2 1,5-diphenyl-3-[3-(thienyl-2-carbonyl)-isoxazole-4-carbonyl]-1H-pyrazole-4-carbonitrile 
• 1426835-26-8 5-phenyl-3-[3-(thienyl-2-carbonyl)-isoxazole-4-carbonyl]-1-p-tolyl-1H-pyrazole-4-carbonitrile 
• 1310876-62-0 [4-(8,9-dimethoxy-1-(4-chlorophenyl)-1,5,6,10b-tetrahydro[1,2,4]triazolo[3,4-a]isoquinoline-3-carbonyl)-isoxazol-3-yl](2-thienyl)methanone 
• 1310876-61-9 [4-(8,9-dimethoxy-1-(4-methylphenyl)-1,5,6,10b-tetrahydro[1,2,4]triazolo[3,4-a]isoquinoline-3-carbonyl)-isoxazol-3-yl](2-thienyl)methanone 
• 1310876-60-8 [4-(8,9-dimethoxy-1-phenyl-1,5,6,10b-tetrahydro[1,2,4]-triazolo[3,4-a]isoquinoline-3-carbonyl)isoxazol-3-yl]-(2-thienyl)methanone 

Relevant articles and documents

Discovery of Hydroxyamidine Derivatives as Highly Potent, Selective Indoleamine-2,3-dioxygenase 1 Inhibitors

In this study, a series of novel hydroxyamidine derivatives were identified as potent and selective IDO1 inhibitors by structure-based drug design. Among them, compounds 13-15 and 18 exhibited favorable enzymatic and cellular activities. Compound 18 showed improved bioavailability in mouse, rat, and dog (F% = 44%, 58.8%, 102.1%, respectively). With reasonable in vivo pharmacokinetic properties, compound 18 was further evaluated in a transgenic MC38 xenograft mouse model. The combination of compound 18 with PD-1 monoclonal antibody showed a synergistic antitumor effect. These data indicated that compound 18 as a potential cancer immunotherapy agent should warrant further investigation.